IL-6 modulating drugs may reduce patients' risk of severe post-COVID-19 outcomes.<h4>Methods</h4>We conducted an emulated target trial in a retrospective cohort of patients with moderate-to-severe rheumatoid arthritis who were prescribed IL-6 receptor antagonists (sarilumab or tocilizumab, pooled treatment) or other biologic agents (anakinra or baricitinib, pooled comparator) in 2022. The gene discussed is IL6; the disease is COVID-19.